Drugs Made In America Acquisition Corp. (DMAA) 2025年第一季度财报(10-Q).pdf

1、 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549 FORM 10-Q(Mark One)QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31,2025 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT

2、OF 1934 For the transition period from _ to _ Commission File Number:001-42467 DRUGS MADE IN AMERICA ACQUISITION CORP.(Exact name of registrant as specified in its charter)Cayman Islands 99-2394788(State or other jurisdiction ofincorporation or organization)(I.R.S.EmployerIdentification No.)1 East B

3、roward Boulevard,Suite 700Fort Lauderdale,FL 33301(Address of principal executive offices,including zip code)(954)870-3099(Registrants telephone number,including area code)N/A(Former name,former address and former fiscal year,if changed since last report)Securities registered pursuant to Section 12(

4、b)of the Act:Title of each class Trading Symbol(s)Name of each exchange on whichregisteredUnits DMAAU The Nasdaq Stock Market LLCOrdinary Shares DMAA The Nasdaq Stock Market LLCRights DMAAR The Nasdaq Stock Market LLC Indicate by check mark whether the registrant(1)has filed all reports required to

5、be filed by Section 13 or 15(d)of theSecurities Exchange Act of 1934 during the preceding 12 months(or for such shorter period that the registrant was required to filesuch reports),and(2)has been subject to such filing requirements for the past 90 days.Yes No Indicate by check mark whether the regis

6、trant has submitted electronically every Interactive Data File required to besubmitted pursuant to Rule 405 of Regulation S-T(232.405 of this chapter)during the preceding 12 months(or for such shorterperiod that the registrant was required to submit such files).Yes No Indicate by check mark whether